Binding proteins specific for lox1 and uses thereof 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2016050889 A1 2016-04-07 [WO201650889] / 2016-04-07
申请号/申请日
2015WO-EP72644 / 2015-09-30
发明人
BUCHANAN ANDREW;CHODORGE MATTHIEU;CARIUK PETER;HUSMARK JOHANNA;BALENDRAN CLARE;PANDEY DEEPESH;CHANG FUMIN;BERKOWITZ DANIEL;ROMER LEWIS;
申请人
MEDIMMUNE;
主分类号
IPC分类号
C07K-016/28C12N-015/113
摘要
(WO201650889) This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins.  In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity.  In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2014US-62058254 2014-10-01
主权利要求
(WO201650889) 1. An isolated LOX1 -binding protein comprising a set of complementary determining regions (CDRs): heavy chain variable region (VH)-CDRl, VH-CDR2, VH-CDR3, and light chain variable region (VL)-CDRl, VL-CDR2 and VL-CDR3, wherein the set of CDRs has a total of 18 or fewer aminoacid substitutions, deletions, and/or insertions from a reference set of CDRs in which: (i) VH-CDR1 has the aminoacid sequence of SEQ ID NO: l; (ii) VH-CDR2 has the aminoacid sequence of SEQ ID NO:5; (iii) VH-CDR3 has the aminoacid sequence of SEQ ID NO: 14; (iv) VL-CDR1 has the aminoacid sequence of SEQ ID NO:30; (v) VL-CDR2 has the aminoacid sequence of SEQ ID NO:31; and (vi) VL-CDR3 has the aminoacid sequence of SEQ ID NO:32.  2. An isolated LOX1 -binding protein comprising a set of complementary determining regions (CDRs): heavy chain variable region (VH)-CDRl, VH-CDR2, VH-CDR3, and light chain variable region (VL)-CDRl, VL-CDR2 and VL-CDR3, wherein: (a) (i) VH-CDR1 has the aminoacid sequence of SEQ ID NO: 1 ; (ii) VH-CDR2 has the aminoacid sequence of SEQ ID NO:2; (iii) VH-CDR3 has the aminoacid sequence of SEQ ID NO:3; (iv) VL-CDR1 has the aminoacid sequence of SEQ ID NO:30; (v) VL-CDR2 has the aminoacid sequence of SEQ ID NO:31 ; and (vi) VL-CDR3 has the aminoacid sequence of SEQ ID NO:32; (b) (i) VH-CDR1 has the aminoacid sequence of SEQ ID NO: 1 ; (ii) VH-CDR2 has the aminoacid sequence of SEQ ID NO:5; (iii) VH-CDR3 has the aminoacid sequence of SEQ ID NO: 14; (iv) VL-CDR1 has the aminoacid sequence of SEQ ID NO:30; (v) VL-CDR2 has the aminoacid sequence of SEQ ID NO:31; and (vi) VL-CDR3 has the aminoacid sequence of SEQ ID NO:32; (c) (i) VH-CDR1 has the aminoacid sequence of SEQ ID NO:38; (ii) VH-CDR2 has the aminoacid sequence of SEQ ID NO:39; (iii) VH-CDR3 has the aminoacid sequence of SEQ ID NO:44; (iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:55; (v) VL-CDR2 has the aminoacid sequence of SEQ ID NO:60; and (vi) VL-CDR3 has the aminoacid sequence of SEQ ID NO:61; or (d) (i) VH-CDR1 has the aminoacid sequence of SEQ ID NO:38; (ii) VH-CDR2 has the aminoacid sequence of SEQ ID NO:39; (iii) VH-CDR3 has the aminoacid sequence of SEQ ID NO:40; (iv) VL-CDR1 has the aminoacid sequence of SEQ ID NO:55; (v) VL-CDR2 has the aminoacid sequence of SEQ ID NO:56; and (vi) VL-CDR3 has the aminoacid sequence of SEQ ID NO:57.  3. An isolated LOXl -binding protein comprising a heavy chain variable region (VH) having at least 90, 95, 97, 98 or 99% sequence identity to SEQ ID NOs:4, 19-29, 41, or 48-54; and a light chain variable region (VL) having at least 90, 95, 97, 98 or 99% sequence identity to SEQ ID NOs:33, 36, 37, 58 or 65-70.  4. An isolated LOXl -binding protein comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH sequence has a total of 15 or fewer aminoacid substitutions, deletions, and/or insertions from a reference VH sequence selected from the group consisting of SEQ ID NO: NO:4, 19-28 and 29, and the VL sequence has a total of 6 or fewer aminoacid substitutions, additions and/or deletions from a reference VL sequence selected from the group consisting of SEQ ID NO:33, 36, and 37.  5. An isolated LOXl -binding protein comprising a heavy chain variable region (VH) selected from the group consisting of: a VH comprising SEQ ID NO:4, 19-29, 41, or 48- 54 and a light chain variable region (VL) selected from the group consisting of a VL comprising SEQ ID NO:33, 36, 37, 58 or 65-70.  6. An isolated LOXl-binding protein comprising a heavy chain variable region (VH) and a light chain variable region (VL) selected from the group consisting of: (a) a VH having the aminoacid sequence of SEQ ID NO:4 and a VL having the aminoacid sequence of SEQ ID NO: 33; (b) a VH having the aminoacid sequence of SEQ ID NO:29 and a VL having the aminoacid sequence of SEQ ID NO: 33; (c) a VH having the aminoacid sequence of SEQ ID NO:41 and a VL having the aminoacid sequence of SEQ ID NO: 58 and (d) a VH having the aminoacid sequence of SEQ ID NO:54 and a VL having the aminoacid sequence of SEQ ID NO:70.  7. An isolated LOXl-binding protein comprising a heavy chain variable region (VH) comprising SEQ ID NO:4 and a light chain variable region (VL) comprising SEQ ID NO:33.  8. An isolated LOXl-binding protein comprising a set of complementary determining regions (CDRs): heavy chain variable region (VH)-CDRl, VH-CDR2, VH-CDR3, and light chain variable region (VL)-CDRl, VL-CDR2 and VL-CDR3 as shown in Table 1, Figure 4 or Figure 5.  9. An isolated LOXl-binding protein comprising a heavy chain variable region (VH) and a light chain variable region (VL) as shown in Table 1, Figure 4 or Figure 5.  10. An isolated LOXl-binding protein comprising a set of complementary determining regions (CDRs): heavy chain variable region (VH)-CDRl, VH-CDR2, VH-CDR3, and light chain variable region (VL)-CDRl, VL-CDR2 and VL-CDR3 wherein: (a) VH-CDR1 comprises the aminoacid sequence: E L S M H (SEQ ID NO: 1); (b) VH-CDR2 comprises the aminoacid sequence: G F D P E D HXi HX2 HX3 HX4 HX5 HX6 Q K F Q G (SEQ ID NO: 71); wherein HXl is selected from the group consisting of G, W, Y and F, HX2 is selected from the group consisting of E, T, Q, K, A, and S, HX3 is selected from the group consisting of T, Y, I, and N, HX4 is selected from the group consisting of I, A, R and H, HX5 is selected from the group consisting of Y, V, T, L and Q, and HX6 is selected from the group consisting of A, D, G, S and H; (c) VH-CDR3 comprises the aminoacid sequence: HX7 HX8 G HX9 HX10 HXn HX12 GVRGWDYYYGMDV (SEQ ID NO: 72); wherein HX7 is selected from the group consisting of P, S and V, HX8 is selected from the group consisting of N, W, D, and T, HX9 is selected from the group consisting of Q, R and T, HX10 is selected from the group consisting of Q and H, HXl 1 is selected from the group consisting of G and Q, and HX12 is selected from the group consisting of K and G; (d) VL-CDR1 comprises the aminoacid sequence: TGSSSNIGAGYDVH (SEQ ID NO: 30); (e) VL-CDR2 comprises the aminoacid sequence: G N S N R P S (SEQ ID NO: 31); and (f) VL-CDR3 comprises the aminoacid sequence: Q S Y D S LXi LX2 LX3 LX4 LX5 LX6 (SEQ ID NO: 73); wherein LXI is selected from the group consisting of M and S, LX2 is selected from the group consisting of L, Y and H, LX3 is selected from the group consisting of S and R, LX4 is selected from the group consisting of A and G or is omitted (no aminoacid), LX5 is selected from the group consisting of W and F, and LX6 is selected from the group consisting of V, G and A.
法律状态
(WO201650889) LEGAL DETAILS FOR WO2016050889  Actual or expected expiration date=2018-04-01    Legal state=ALIVE    Status=PENDING     Event publication date=2015-09-30  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOEP2015072644  Application date=2015-09-30  Standardized application number=2015WO-EP72644     Event publication date=2016-04-07  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO2016050889  Publication stage Code=A1  Publication date=2016-04-07  Standardized publication number=WO201650889  LEGAL DETAILS FOR DESIGNATED STATE AU2015326891  Actual or expected expiration date=2035-09-30    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=AU Corresponding appl: AU2015326891  Application date in the designated or member state=2015-09-30   Application number in the designated or member state=2015AU-0326891 Corresponding cc:  Designated or member state=AU Corresponding pat: AU2015326891  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-03-23   Publication number in the designated or member state=AU2015326891    Event publication date=2017-03-23  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=AU  LEGAL DETAILS FOR DESIGNATED STATE BR112017006609  Actual or expected expiration date=2035-09-30    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=BR Corresponding appl: BR112017006609  Application date in the designated or member state=2015-09-30   Application number in the designated or member state=2017BR-0006609 Corresponding cc:  Designated or member state=BR Corresponding pat: BR112017006609  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-04-11   Publication number in the designated or member state=BR112017006609    Event publication date=2017-04-11  Event code=WO/REG  Event code=BR/B01A  Event type=Examination events  Reference to a national code Pct publication - request for entry into the national phase Comunicacao da publicacao internacional pct. apresentacao de peticao de requerimento de entrada na fase nacional Corresponding cc:  Designated or member state=BR  LEGAL DETAILS FOR DESIGNATED STATE CA2962731  Actual or expected expiration date=2035-09-30    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=CA Corresponding appl: CA2962731  Application date in the designated or member state=2015-09-30   Application number in the designated or member state=2015CA-2962731 Corresponding cc:  Designated or member state=CA Corresponding pat: CA2962731  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2016-04-07   Publication number in the designated or member state=CA2962731    Event publication date=2017-03-27  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=CA  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2017-04-03    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2017-04-03  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE EP3201233  Actual or expected expiration date=2035-09-30    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=EP Corresponding appl: EP15784930  Application date in the designated or member state=2015-09-30   Application number in the designated or member state=2015EP-0784930 Corresponding cc:  Designated or member state=EP Corresponding pat: EP3201233  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-08-09   Publication number in the designated or member state=EP3201233    Event publication date=2016-05-18  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP     Event publication date=2017-04-26  Event code=WO/REEP  Event indicator=Pos  Event type=Entry into national phase  Request for entry into the European phase Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE IL250796  Actual or expected expiration date=2035-09-30    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=IL Corresponding appl: IL25079617  Application date in the designated or member state=2017-02-26   Application number in the designated or member state=2017IL-0250796 Corresponding cc:  Designated or member state=IL Corresponding pat: IL250796  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2017-04-30   Publication number in the designated or member state=IL-250796    Event publication date=2017-02-26  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=IL  LEGAL DETAILS FOR DESIGNATED STATE JP  Actual or expected expiration date=2034-10-01    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=JP Corresponding appl: JP2017517234    Event publication date=2017-03-30  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=JP  LEGAL DETAILS FOR DESIGNATED STATE KR20170062502  Actual or expected expiration date=2035-09-30    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=KR Corresponding appl: KR20177011186  Application date in the designated or member state=2015-09-30   Application number in the designated or member state=2017KR-7011186 Corresponding cc:  Designated or member state=KR Corresponding pat: KR20170062502  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2017-06-07   Publication number in the designated or member state=KR20170062502    Event publication date=2017-04-25  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=KR  LEGAL DETAILS FOR DESIGNATED STATE RU  Actual or expected expiration date=2034-10-01    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=RU Corresponding appl: RU2017115071    Event publication date=2017-05-02  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=RU  LEGAL DETAILS FOR DESIGNATED STATE SG11201702385T  Actual or expected expiration date=2035-09-30    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=SG Corresponding appl: SG11201702385  Application date in the designated or member state=2015-09-30   Corresponding cc:  Designated or member state=SG Corresponding pat: SG11201702385T  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2017-04-27   Publication number in the designated or member state=SG11201702385T
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部